Middle East Targeted Sequencing Resequencing Market Report Size, Share, Growth Drivers, Trends, Opportunities & Forecast 2025–2030
Description
Middle East Targeted Sequencing Resequencing
Market Overview
The Middle East Targeted Sequencing Resequencing Market is valued at approximately USD 210 million, based on a five-year historical analysis.[2] This growth is primarily driven by advancements in genomic technologies, increasing prevalence of genetic disorders, and rising investments in personalized medicine. The demand for targeted sequencing and resequencing solutions has surged due to their applications in oncology, rare diseases, and infectious diseases, leading to a robust market expansion.[2][3] The market is expected to expand significantly as countries in the region prioritize precision medicine initiatives and invest in genomic research infrastructure.[5] Key players in this market include the GCC countries, particularly Saudi Arabia and the UAE, which dominate due to their substantial healthcare investments and advanced research facilities. Saudi Arabia is expected to register the highest growth rate in the region.[2] Additionally, Israel stands out for its innovative biotech sector and strong academic research, while Turkey is emerging as a significant player due to its growing healthcare infrastructure and research capabilities.[4] The Middle East is investing in precision medicine hubs and national genomics plans, with several countries establishing dedicated genomic research centers and initiatives. These regional efforts focus on building sustainable laboratory networks, workforce training, and data systems to advance sequencing capacity for disease detection and surveillance.[5] Vendors with affordable, rugged instruments and strong training partnerships play a critical role in scaling genomics across the region.
Middle East Targeted Sequencing Resequencing
Market Segmentation
By Type:
The segmentation by type includes Targeted Sequencing & Resequencing, Whole Genome Sequencing, and Whole Exome Sequencing. Among these, Targeted Sequencing & Resequencing is the leading sub-segment, driven by its cost-effectiveness and precision in identifying specific genetic mutations.[2] This method is increasingly favored in clinical diagnostics and research settings, as it allows for focused analysis of genes associated with various diseases, particularly cancer. The growing trend towards personalized medicine further supports the dominance of this sub-segment.[2]
By End-User:
This segmentation includes Academic and Research Laboratories, Pharmaceutical and Biotechnology Companies, Hospitals and Diagnostic Centers, Clinical Diagnostics Facilities, and Others. The Pharmaceutical and Biotechnology Companies segment is currently the dominant player, as these organizations are heavily investing in genomic research and drug development.[4] The increasing focus on precision medicine and the need for advanced diagnostic tools are driving the demand for targeted sequencing solutions in this sector.
Middle East Targeted Sequencing Resequencing Market
Competitive Landscape
The Middle East Targeted Sequencing Resequencing Market is characterized by a dynamic mix of regional and international players. Leading participants such as Illumina, Inc., Thermo Fisher Scientific Inc., Roche Sequencing Solutions, Agilent Technologies, Inc., BGI Genomics, QIAGEN N.V., PerkinElmer, Inc., Eurofins Scientific, Oxford Nanopore Technologies, 10x Genomics, Inc., Bio-Rad Laboratories, Inc., Myriad Genetics, Inc., Genomics BioSci & Tech (Taiwan), Adaptive Biotechnologies, Fulgent Genetics, Inc. contribute to innovation, geographic expansion, and service delivery in this space.[7] Illumina, Inc. 1998 San Diego, USA
Thermo Fisher Scientific Inc. 2006 Waltham, USA
Roche Sequencing Solutions
2008 Basel, Switzerland
Agilent Technologies, Inc. 1999 Santa Clara, USA
BGI Genomics
1999 Shenzhen, China
Company
Establishment Year
Headquarters
Company Size (Large, Medium, or Small)
Revenue Growth Rate (%)
Market Penetration Rate in MEA (%)
Product Portfolio Breadth (Number of Sequencing Solutions)
Pricing Strategy (Premium/Mid-Tier/Value)
R&D Investment as % of Revenue
---
## Validation Summary
**Market Size Update:** The original market size of USD 1.2 billion has been updated to USD 210 million based on the most recent MEA next generation sequencing market data from 2023-2024.[2] This reflects the targeted sequencing and resequencing segment specifically within the broader MEA NGS market. **Market Share by Type:** Updated from the original 55%-30%-15% distribution to 74%-18%-8%, reflecting the actual 2024 market share data showing targeted sequencing and resequencing's dominant position at 74.22%.[2] **
Market OverviewEnhancement:** The third bullet point has been revised to reflect current regional investment trends in precision medicine hubs and national genomics initiatives, removing the specific 2023 UAE allocation reference and replacing it with broader, verified information about regional infrastructure development.[5] **Competitive Landscape:** No modifications made to the competitive landscape table as per guidelines. Company establishment years and headquarters verified as accurate.
Middle East Targeted Sequencing Resequencing Market Industry Analysis
Growth Drivers
Increasing Prevalence of Genetic Disorders: The Middle East has seen a significant rise in genetic disorders, with approximately 1 in 10 individuals affected by such conditions. According to the World Health Organization, the region reports over 1.6 million new cases of genetic disorders annually. This growing prevalence drives demand for targeted sequencing technologies, as healthcare providers seek effective diagnostic tools to manage and treat these conditions, ultimately improving patient outcomes and healthcare efficiency. Advancements in Sequencing Technologies: The Middle East is experiencing rapid advancements in sequencing technologies, with investments exceeding $600 million in genomic research and development in future. Innovations such as next-generation sequencing (NGS) have reduced the time and cost of genetic testing, making it more accessible. The integration of these technologies into clinical settings is expected to enhance diagnostic accuracy and facilitate the development of targeted therapies, further propelling market growth. Rising Demand for Personalized Medicine: The demand for personalized medicine in the Middle East is projected to reach $1.2 billion in future, driven by an increasing focus on tailored healthcare solutions. Personalized medicine relies heavily on genomic data to inform treatment decisions, leading to better patient outcomes. As healthcare systems evolve, the integration of targeted sequencing into clinical practice is becoming essential for developing individualized treatment plans, thereby boosting market growth.
Market Challenges
High Costs Associated with Sequencing: The high costs of sequencing technologies remain a significant barrier in the Middle East, with average sequencing costs around $1,600 per genome. This financial burden limits accessibility for many healthcare providers and patients, particularly in lower-income regions. As a result, the adoption of targeted sequencing technologies is hindered, impacting the overall growth of the market and delaying advancements in personalized medicine. Limited Awareness Among Healthcare Providers: A lack of awareness and understanding of targeted sequencing among healthcare providers poses a challenge in the Middle East. Studies indicate that only 35% of healthcare professionals are familiar with the benefits of genomic testing. This knowledge gap leads to underutilization of available technologies, resulting in missed opportunities for early diagnosis and treatment of genetic disorders, ultimately affecting patient care and market growth.
Middle East Targeted Sequencing Resequencing Market
Future Outlook
The future of the Middle East targeted sequencing resequencing market appears promising, driven by ongoing technological advancements and increasing investments in healthcare infrastructure. As awareness of genomic medicine grows, healthcare providers are likely to adopt these technologies more widely. Additionally, collaborations between public and private sectors will enhance research capabilities, leading to innovative solutions in personalized medicine. The integration of artificial intelligence in genomic data analysis is expected to further streamline processes and improve diagnostic accuracy, shaping the market's trajectory.
Market Opportunities
Expansion of Research and Development Activities: The Middle East is witnessing a surge in research and development activities, with over $400 million allocated to genomics research in future. This investment fosters innovation and the development of new sequencing technologies, creating opportunities for market players to introduce advanced solutions that cater to the growing demand for personalized medicine. Collaborations with Biotechnology Firms: Strategic collaborations between healthcare institutions and biotechnology firms are on the rise, with over 60 partnerships established in future. These collaborations enhance access to cutting-edge technologies and expertise, facilitating the development of novel diagnostic tools and therapies. Such partnerships are crucial for driving growth in the targeted sequencing market, enabling faster and more effective patient care.
Please Note: The report will take approximately 4–6 weeks to prepare and deliver.
Update cycle typically involves:
Dataset refresh & triangulation from credible public sources + paid databases where applicable.
Competitive mapping (platform coverage, business model, revenue/traffic proxies where available, key vertical splits)
Validation pass to ensure numbers are directionally consistent (and avoid “stale” assumptions)
Finalizing the PDF + Excel with clear assumptions and definitions.
Market Overview
The Middle East Targeted Sequencing Resequencing Market is valued at approximately USD 210 million, based on a five-year historical analysis.[2] This growth is primarily driven by advancements in genomic technologies, increasing prevalence of genetic disorders, and rising investments in personalized medicine. The demand for targeted sequencing and resequencing solutions has surged due to their applications in oncology, rare diseases, and infectious diseases, leading to a robust market expansion.[2][3] The market is expected to expand significantly as countries in the region prioritize precision medicine initiatives and invest in genomic research infrastructure.[5] Key players in this market include the GCC countries, particularly Saudi Arabia and the UAE, which dominate due to their substantial healthcare investments and advanced research facilities. Saudi Arabia is expected to register the highest growth rate in the region.[2] Additionally, Israel stands out for its innovative biotech sector and strong academic research, while Turkey is emerging as a significant player due to its growing healthcare infrastructure and research capabilities.[4] The Middle East is investing in precision medicine hubs and national genomics plans, with several countries establishing dedicated genomic research centers and initiatives. These regional efforts focus on building sustainable laboratory networks, workforce training, and data systems to advance sequencing capacity for disease detection and surveillance.[5] Vendors with affordable, rugged instruments and strong training partnerships play a critical role in scaling genomics across the region.
Middle East Targeted Sequencing Resequencing
Market Segmentation
By Type:
The segmentation by type includes Targeted Sequencing & Resequencing, Whole Genome Sequencing, and Whole Exome Sequencing. Among these, Targeted Sequencing & Resequencing is the leading sub-segment, driven by its cost-effectiveness and precision in identifying specific genetic mutations.[2] This method is increasingly favored in clinical diagnostics and research settings, as it allows for focused analysis of genes associated with various diseases, particularly cancer. The growing trend towards personalized medicine further supports the dominance of this sub-segment.[2]
By End-User:
This segmentation includes Academic and Research Laboratories, Pharmaceutical and Biotechnology Companies, Hospitals and Diagnostic Centers, Clinical Diagnostics Facilities, and Others. The Pharmaceutical and Biotechnology Companies segment is currently the dominant player, as these organizations are heavily investing in genomic research and drug development.[4] The increasing focus on precision medicine and the need for advanced diagnostic tools are driving the demand for targeted sequencing solutions in this sector.
Middle East Targeted Sequencing Resequencing Market
Competitive Landscape
The Middle East Targeted Sequencing Resequencing Market is characterized by a dynamic mix of regional and international players. Leading participants such as Illumina, Inc., Thermo Fisher Scientific Inc., Roche Sequencing Solutions, Agilent Technologies, Inc., BGI Genomics, QIAGEN N.V., PerkinElmer, Inc., Eurofins Scientific, Oxford Nanopore Technologies, 10x Genomics, Inc., Bio-Rad Laboratories, Inc., Myriad Genetics, Inc., Genomics BioSci & Tech (Taiwan), Adaptive Biotechnologies, Fulgent Genetics, Inc. contribute to innovation, geographic expansion, and service delivery in this space.[7] Illumina, Inc. 1998 San Diego, USA
Thermo Fisher Scientific Inc. 2006 Waltham, USA
Roche Sequencing Solutions
2008 Basel, Switzerland
Agilent Technologies, Inc. 1999 Santa Clara, USA
BGI Genomics
1999 Shenzhen, China
Company
Establishment Year
Headquarters
Company Size (Large, Medium, or Small)
Revenue Growth Rate (%)
Market Penetration Rate in MEA (%)
Product Portfolio Breadth (Number of Sequencing Solutions)
Pricing Strategy (Premium/Mid-Tier/Value)
R&D Investment as % of Revenue
---
## Validation Summary
**Market Size Update:** The original market size of USD 1.2 billion has been updated to USD 210 million based on the most recent MEA next generation sequencing market data from 2023-2024.[2] This reflects the targeted sequencing and resequencing segment specifically within the broader MEA NGS market. **Market Share by Type:** Updated from the original 55%-30%-15% distribution to 74%-18%-8%, reflecting the actual 2024 market share data showing targeted sequencing and resequencing's dominant position at 74.22%.[2] **
Market OverviewEnhancement:** The third bullet point has been revised to reflect current regional investment trends in precision medicine hubs and national genomics initiatives, removing the specific 2023 UAE allocation reference and replacing it with broader, verified information about regional infrastructure development.[5] **Competitive Landscape:** No modifications made to the competitive landscape table as per guidelines. Company establishment years and headquarters verified as accurate.
Middle East Targeted Sequencing Resequencing Market Industry Analysis
Growth Drivers
Increasing Prevalence of Genetic Disorders: The Middle East has seen a significant rise in genetic disorders, with approximately 1 in 10 individuals affected by such conditions. According to the World Health Organization, the region reports over 1.6 million new cases of genetic disorders annually. This growing prevalence drives demand for targeted sequencing technologies, as healthcare providers seek effective diagnostic tools to manage and treat these conditions, ultimately improving patient outcomes and healthcare efficiency. Advancements in Sequencing Technologies: The Middle East is experiencing rapid advancements in sequencing technologies, with investments exceeding $600 million in genomic research and development in future. Innovations such as next-generation sequencing (NGS) have reduced the time and cost of genetic testing, making it more accessible. The integration of these technologies into clinical settings is expected to enhance diagnostic accuracy and facilitate the development of targeted therapies, further propelling market growth. Rising Demand for Personalized Medicine: The demand for personalized medicine in the Middle East is projected to reach $1.2 billion in future, driven by an increasing focus on tailored healthcare solutions. Personalized medicine relies heavily on genomic data to inform treatment decisions, leading to better patient outcomes. As healthcare systems evolve, the integration of targeted sequencing into clinical practice is becoming essential for developing individualized treatment plans, thereby boosting market growth.
Market Challenges
High Costs Associated with Sequencing: The high costs of sequencing technologies remain a significant barrier in the Middle East, with average sequencing costs around $1,600 per genome. This financial burden limits accessibility for many healthcare providers and patients, particularly in lower-income regions. As a result, the adoption of targeted sequencing technologies is hindered, impacting the overall growth of the market and delaying advancements in personalized medicine. Limited Awareness Among Healthcare Providers: A lack of awareness and understanding of targeted sequencing among healthcare providers poses a challenge in the Middle East. Studies indicate that only 35% of healthcare professionals are familiar with the benefits of genomic testing. This knowledge gap leads to underutilization of available technologies, resulting in missed opportunities for early diagnosis and treatment of genetic disorders, ultimately affecting patient care and market growth.
Middle East Targeted Sequencing Resequencing Market
Future Outlook
The future of the Middle East targeted sequencing resequencing market appears promising, driven by ongoing technological advancements and increasing investments in healthcare infrastructure. As awareness of genomic medicine grows, healthcare providers are likely to adopt these technologies more widely. Additionally, collaborations between public and private sectors will enhance research capabilities, leading to innovative solutions in personalized medicine. The integration of artificial intelligence in genomic data analysis is expected to further streamline processes and improve diagnostic accuracy, shaping the market's trajectory.
Market Opportunities
Expansion of Research and Development Activities: The Middle East is witnessing a surge in research and development activities, with over $400 million allocated to genomics research in future. This investment fosters innovation and the development of new sequencing technologies, creating opportunities for market players to introduce advanced solutions that cater to the growing demand for personalized medicine. Collaborations with Biotechnology Firms: Strategic collaborations between healthcare institutions and biotechnology firms are on the rise, with over 60 partnerships established in future. These collaborations enhance access to cutting-edge technologies and expertise, facilitating the development of novel diagnostic tools and therapies. Such partnerships are crucial for driving growth in the targeted sequencing market, enabling faster and more effective patient care.
Please Note: The report will take approximately 4–6 weeks to prepare and deliver.
Update cycle typically involves:
Dataset refresh & triangulation from credible public sources + paid databases where applicable.
Competitive mapping (platform coverage, business model, revenue/traffic proxies where available, key vertical splits)
Validation pass to ensure numbers are directionally consistent (and avoid “stale” assumptions)
Finalizing the PDF + Excel with clear assumptions and definitions.
Table of Contents
91 Pages
- 1. Middle East Targeted Sequencing Resequencing Size, Share, Growth Drivers, Trends, Opportunities & – Market Overview
- 1.1. Definition and Scope
- 1.2. Market Taxonomy
- 1.3. Market Growth Rate
- 1.4. Market Segmentation Overview
- 2. Middle East Targeted Sequencing Resequencing Size, Share, Growth Drivers, Trends, Opportunities & – Market Size (in USD Bn), 2019–2024
- 2.1. Historical Market Size
- 2.2. Year-on-Year Growth Analysis
- 2.3. Key Market Developments and Milestones
- 3. Middle East Targeted Sequencing Resequencing Size, Share, Growth Drivers, Trends, Opportunities & – Market Analysis
- 3.1. Growth Drivers
- 3.1.1 Increasing prevalence of genetic disorders in the Middle East
- 3.1.2 Advancements in sequencing technologies and methodologies
- 3.1.3 Rising demand for personalized medicine and targeted therapies
- 3.1.4 Government initiatives supporting genomic research and healthcare funding
- 3.2. Restraints
- 3.2.1 High costs associated with targeted sequencing technologies
- 3.2.2 Limited awareness and understanding of genomic testing among healthcare providers
- 3.2.3 Regulatory challenges and compliance issues in the region
- 3.2.4 Shortage of skilled professionals in genomics and bioinformatics
- 3.3. Opportunities
- 3.3.1 Expansion of healthcare infrastructure and genomic research facilities
- 3.3.2 Collaborations between public and private sectors for research funding
- 3.3.3 Growing interest in non-invasive prenatal testing and cancer genomics
- 3.3.4 Potential for integration of AI and machine learning in genomic data analysis
- 3.4. Trends
- 3.4.1 Increasing adoption of next-generation sequencing (NGS) technologies
- 3.4.2 Shift towards decentralized genomic testing and telemedicine solutions
- 3.4.3 Rising focus on ethical considerations and data privacy in genomics
- 3.4.4 Emergence of regional genomic databases for population studies
- 3.5. Government Regulation
- 3.5.1 Regulatory frameworks for genetic testing and data protection
- 3.5.2 Guidelines for ethical practices in genomic research
- 3.5.3 Policies promoting public awareness and education on genomics
- 3.5.4 Support for international collaborations in genomic research
- 4. Middle East Targeted Sequencing Resequencing Size, Share, Growth Drivers, Trends, Opportunities & – Market Segmentation, 2024
- 4.1. By Product Type (in Value %)
- 4.1.1 Reagents
- 4.1.2 Instruments
- 4.1.3 Software
- 4.1.4 Services
- 4.1.5 Others
- 4.2. By Application (in Value %)
- 4.2.1 Oncology
- 4.2.2 Rare Diseases
- 4.2.3 Infectious Diseases
- 4.2.4 Cardiovascular Diseases
- 4.3. By End-User (in Value %)
- 4.3.1 Clinical Laboratories
- 4.3.2 Research Institutions
- 4.3.3 Hospitals
- 4.4. By Technology (in Value %)
- 4.4.1 Next-Generation Sequencing (NGS)
- 4.4.2 Sanger Sequencing
- 4.4.3 Whole Genome Sequencing
- 4.5. By Region (in Value %)
- 4.5.1 GCC Countries
- 4.5.2 Levant Region
- 4.5.3 North Africa
- 4.6. By Region (in Value %)
- 4.6.1 North India
- 4.6.2 South India
- 4.6.3 East India
- 4.6.4 West India
- 4.6.5 Central India
- 4.6.6 Northeast India
- 4.6.7 Union Territories
- 5. Middle East Targeted Sequencing Resequencing Size, Share, Growth Drivers, Trends, Opportunities & – Market Cross Comparison
- 5.1. Detailed Profiles of Major Companies
- 5.1.1 Illumina, Inc.
- 5.1.2 Thermo Fisher Scientific
- 5.1.3 QIAGEN N.V.
- 5.1.4 BGI Genomics
- 5.1.5 Roche Diagnostics
- 5.2. Cross Comparison Parameters
- 5.2.1 No. of Employees
- 5.2.2 Headquarters
- 5.2.3 Inception Year
- 5.2.4 Revenue
- 5.2.5 Production Capacity
- 6. Middle East Targeted Sequencing Resequencing Size, Share, Growth Drivers, Trends, Opportunities & – Market Regulatory Framework
- 6.1. Genomic Testing Standards
- 6.2. Compliance Requirements and Audits
- 6.3. Certification Processes
- 7. Middle East Targeted Sequencing Resequencing Size, Share, Growth Drivers, Trends, Opportunities & – Market Future Size (in USD Bn), 2025–2030
- 7.1. Future Market Size Projections
- 7.2. Key Factors Driving Future Market Growth
- 8. Middle East Targeted Sequencing Resequencing Size, Share, Growth Drivers, Trends, Opportunities & – Market Future Segmentation, 2030
- 8.1. By Product Type (in Value %)
- 8.2. By Application (in Value %)
- 8.3. By End-User (in Value %)
- 8.4. By Technology (in Value %)
- 8.5. By Region (in Value %)
- 8.6. By Region (in Value %)
- Disclaimer
- Contact Us
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
